CN101301274B - Compound mequindox soluble powder for animals and preparation thereof - Google Patents
Compound mequindox soluble powder for animals and preparation thereof Download PDFInfo
- Publication number
- CN101301274B CN101301274B CN2008100526971A CN200810052697A CN101301274B CN 101301274 B CN101301274 B CN 101301274B CN 2008100526971 A CN2008100526971 A CN 2008100526971A CN 200810052697 A CN200810052697 A CN 200810052697A CN 101301274 B CN101301274 B CN 101301274B
- Authority
- CN
- China
- Prior art keywords
- mequindox
- soluble powder
- compound
- colistin sulfate
- sodium salicylate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- CUJMCPPBTUATEJ-UHFFFAOYSA-N 1-(3-methyl-4-oxido-1-oxoquinoxalin-1-ium-2-yl)ethanone Chemical compound C1=CC=C2[N+](=O)C(C(=O)C)=C(C)N([O-])C2=C1 CUJMCPPBTUATEJ-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 239000000843 powder Substances 0.000 title claims abstract description 46
- 150000001875 compounds Chemical class 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241001465754 Metazoa Species 0.000 title abstract description 13
- 108010078777 Colistin Proteins 0.000 claims abstract description 46
- 229960001127 colistin sulfate Drugs 0.000 claims abstract description 46
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 claims abstract description 46
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims abstract description 37
- 229960004025 sodium salicylate Drugs 0.000 claims abstract description 37
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 29
- 239000008103 glucose Substances 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 241000282898 Sus scrofa Species 0.000 claims description 21
- 208000001848 dysentery Diseases 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 238000007599 discharging Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 230000000694 effects Effects 0.000 abstract description 8
- 241000282887 Suidae Species 0.000 abstract description 6
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 4
- 206010066901 Treatment failure Diseases 0.000 abstract description 3
- 208000015181 infectious disease Diseases 0.000 abstract description 3
- 239000004599 antimicrobial Substances 0.000 abstract description 2
- 238000000034 method Methods 0.000 abstract description 2
- 241000607764 Shigella dysenteriae Species 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 230000035622 drinking Effects 0.000 abstract 2
- 238000011084 recovery Methods 0.000 abstract 1
- 239000000375 suspending agent Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 244000144977 poultry Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a compound mequindox soluble powder for animals and a preparation method thereof, which aims to provide the compound mequindox soluble powder for the animals and the preparation method, wherein, the compound mequindox soluble powder for the animals can treat the complex infection of shigella shigae and colon bacillus of pigs, is quick to take effect, can solve the treatment failure phenomenon caused by feeding and drinking conditions of the pigs during the illness, and improve the rate of liveweight growth; and the preparation method has a simple process and is easy to realize. The powder comprises the compositions in percentage by weight: 2 to 10 percent of mequindox, 0.5 to 5 percent of colistin sulfate, 6 to 30 percent of sodium salicylate, and the balance being oral glucose. The soluble powder is a compound preparation formed by a double antimicrobial drug combined with a suspending agent, has quick effect on the complex infection of the shigella shigae and the colon bacillus of the pigs due to the fact that the mequindox and the colistin sulfate are jointly used, is effective and highly efficient, can solve the treatment failure phenomenon caused by feeding and drinking problems during the illness, accelerate the recovery of the pigs, and increase the weight of the pigs.
Description
Technical field
The present invention relates to a kind of compound mequindox soluble powder for animals and preparation method thereof.
Background technology
Swine dysentery and escherichia coli mixed infection are a kind of diseases that pig often sends out in recent years, the pig digestive system is mainly encroached in swine dysentery and escherichia coli mixed infection, cause serious diarrhoea, and owing to be mixed infection, increased the mortality rate of pig greatly, and the diagnosis of disease caused very big trouble, and bring very big puzzlement for veterinary and raiser, lose for some raiser greatly.
At present, because Mequindox can specific aim be killed the dysentery that the swine dysentery bacillus causes, escherichia coli are also had certain effect, because a large amount of the use and life-time service, drug-resistance of bacteria is very high, the normal phenomenon that the treatment failure occurs.Colistin sulfate is a kind of to the effective medicine of escherichia coli, also because with the same a large amount of uses of Mequindox, cause drug resistance general, therapeutic effect reduces, simultaneously, because the dysentery bacterium in recent years and the ratio of colibacillary MOI increase, and make these two kinds of medicines of independent usefulness not reach satisfactory therapeutic effects.And both are when share, because the Mequindox powder can not be dissolved in water, the colistin sulfate soluble powder is dissolved in water, because these two kinds of medicines can not be all water-soluble, and pig suffers from dysentery and colibacillosis and makes and cause diarrhoea, generally do not like foodstuff and like drinking-water, this feed intake problem that causes because of disease when causing treatment does not reach therapeutic effect.And the raiser uses inconvenience, and it is too high and cause the phenomenon of drug waste to occur certain pharmaceutical quantities deficiency or dosage easily, and the user uses uneconomical.Simultaneously,, be difficult for to judge disease, can not suit the remedy to the case, bring difficulty, sometimes even incur loss through delay golden hour to treatment of diseases for the raiser.
Summary of the invention
The present invention is in order to overcome weak point of the prior art, provide a kind of and can treat swine dysentery and escherichia coli MOI, therapeutic effect is good, and reduces the bacterial drug resistance problem, easy to use, can obviously improve the compound mequindox soluble powder for animals of rate of body weight gain.
It is simple that another object of the present invention provides a kind of technology, easily the preparation method of the above-mentioned compound mequindox soluble powder for animals of realizing.
The present invention is achieved through the following technical solutions:
A kind of compound mequindox soluble powder for animals is characterized in that, is made by following component by weight percentage: Mequindox is 2～10%, and colistin sulfate is 0.5～5%, and sodium salicylate is 6～30%, and surplus is an oral glucose.
Wherein the preferable content of each component is: Mequindox is 3～8%, and colistin sulfate is 1～4%, and sodium salicylate is 9～24%, and surplus is an oral glucose.The optimum content of each component is: Mequindox is 5%, and colistin sulfate is 2%, and sodium salicylate is 15%, and surplus is an oral glucose.
A kind of preparation method of compound mequindox soluble powder for animals is characterized in that, comprises the steps:
(1) Mequindox, colistin sulfate, sodium salicylate and oral glucose are sieved respectively, standby;
(2) good Mequindox, colistin sulfate and sodium salicylate fully mixes in V word mixer to take by weighing sieve;
(3) will sieve good oral glucose again joins in the mixture of above-mentioned Mequindox, colistin sulfate and sodium salicylate, in common batch mixer, fully mix, discharging, sieve and obtain compound mequindox soluble powder of the present invention, make by following component by weight percentage in the compound mequindox soluble powder wherein of the present invention: Mequindox 5～20%, colistin sulfate 0.5～5%, sodium salicylate are 6～30%, and surplus is an oral glucose.
Wherein preferable consisting of: Mequindox 8～15%, colistin sulfate 1～4%, sodium salicylate are 9～24%, surplus is an oral glucose.
Best group becomes: Mequindox 5%, and colistin sulfate 2%, sodium salicylate 15%, surplus is an oral glucose.
The present invention has following technique effect:
The present invention is for adopting two kinds of compound preparations that antimicrobial drug share, Mequindox and colistin sulfate unite use, by to the rational proportion of Mequindox and colistin sulfate consumption and the cooperation hydrotropy of cosolvent sodium salicylate, has double effects, can kill swine dysentery bacillus and escherichia coli, and reduce the treatment that its drug resistance causes and lost efficacy, this product can be dissolved in water fully simultaneously, not liking of can overcoming that swine dysentery bacillus and coli-infection bring searched for food and liked the clinical symptoms of drinking-water, and treatment is accelerated, improve rate of body weight gain, and can avoid drug residue to exceed standard.And the user treats the disease use under the situation that can not distinguish swine dysentery bacillus and escherichia coli MOI more convenient, because drug dose is little, instant effect has reduced use cost.
The preparation method technology of compound mequindox soluble powder for animals of the present invention is simple, realizes easily.
The specific embodiment
Below in conjunction with specific embodiment to the detailed description of the invention.
Embodiment 1
(1) Mequindox, colistin sulfate, sodium salicylate, oral glucose are crossed the 24# sieve respectively, standby.
(2) good Mequindox 2kg fully mixed 30 minutes in V word mixer with colistin sulfate 5kg, sodium salicylate 6kg to take by weighing sieve.
(3) will sieve in the mixture that good oral glucose 87kg joins above-mentioned Mequindox and colistin sulfate, sodium salicylate again, and fully mix 30 minutes in common batch mixer, discharging is crossed the 24# sieve and is obtained compound mequindox soluble powder of the present invention.
Embodiment 2
(1) Mequindox, colistin sulfate, sodium salicylate and oral glucose are crossed the 24# sieve respectively, standby.
(2) good Mequindox 10kg fully mixed 30 minutes in V word mixer with colistin sulfate 0.5kg, sodium salicylate 30kg to take by weighing sieve.
(3) will sieve in the mixture that good oral glucose powder 59.5kg joins above-mentioned Mequindox and colistin sulfate, sodium salicylate again, and fully mix 30 minutes in common batch mixer, discharging is crossed the 24# sieve and is obtained compound mequindox soluble powder of the present invention.
Embodiment 3
(1) Mequindox, colistin sulfate, sodium salicylate and oral glucose are crossed the 24# sieve respectively, standby.
(2) good Mequindox 3kg fully mixed 30 minutes in V word mixer with colistin sulfate 4kg, sodium salicylate 9kg to take by weighing sieve.
(3) will sieve in the mixture that good oral glucose powder 84kg joins above-mentioned Mequindox and colistin sulfate, sodium salicylate again, and fully mix 30 minutes in common batch mixer, discharging is crossed the 24# sieve and is obtained compound mequindox soluble powder of the present invention.
Embodiment 4
(1) Mequindox, colistin sulfate, sodium salicylate and oral glucose are crossed the 24# sieve respectively, standby.
(2) good Mequindox 8kg fully mixed 30 minutes in V word mixer with colistin sulfate 1kg, sodium salicylate 24kg to take by weighing sieve.
(3) will sieve in the mixture that good oral glucose powder 67kg joins above-mentioned Mequindox and colistin sulfate, sodium salicylate again, and fully mix 30 minutes in common batch mixer, discharging is crossed the 24# sieve and is obtained compound mequindox soluble powder of the present invention.
Embodiment 5
(1) Mequindox, colistin sulfate, sodium salicylate and oral glucose are crossed the 24# sieve respectively, standby.
(2) good Mequindox 6kg fully mixed 30 minutes in V word mixer with colistin sulfate 1.5kg, sodium salicylate 24kg to take by weighing sieve.
(3) will sieve in the mixture that good oral glucose powder 68.5kg joins above-mentioned Mequindox and colistin sulfate, sodium salicylate again, and fully mix 30 minutes in common batch mixer, discharging is crossed the 24# sieve and is obtained compound mequindox soluble powder of the present invention.。
Embodiment 6
(1) Mequindox, colistin sulfate, sodium salicylate and oral glucose are crossed the 24# sieve respectively, standby.
(2) take by weighing sieve good Mequindox 5kg and colistin sulfate 2kg, sodium salicylate 15kg, in V word mixer, fully mixed 30 minutes.
(3) will sieve good oral glucose 78kg again and join in the mixture of above-mentioned Mequindox and colistin sulfate, and fully mix 30 minutes in common batch mixer, discharging is crossed the 24# sieve and is obtained compound mequindox soluble powder of the present invention.
Clinical trial:
1. laboratory animal:
Only 100 of the ill one-tenth of picked at random pigs, body weight is at 30～60kg.
2. experiment medicine
The compound mequindox soluble powder our unit development of the embodiment of the invention 6 preparations;
5% Mequindox powder our unit prepared in laboratory;
2% colistin sulfate powder our unit prepared in laboratory.
3. experimental technique:
Suffer from pig with 100 and be divided into four groups at random by body weight, 25 every group.
The A group does not give Drug therapy for the blank group.
The B group is treated usage with 10% Mequindox powder: spice is for oral administration, every 1kg body weight 0.2g, 2 times on the one, logotype 4 days.
The C group is treated usage with 2% colistin sulfate: drinking-water is for oral administration, every 1kg body weight 0.2g, 2 times on the one, logotype 4 days.
The D group is treated usage with the compound mequindox soluble powder of the embodiment of the invention 6 preparations: drinking-water is for oral administration, every 1kg body weight 0.2g, 2 times on the one, logotype 2 days.
After the treatment beginning, every day, record trouble poultry health situation of change and dead animal distributed, and treat and add up therapeutic effect after 10 days, wherein:
Invalid: as after referring to 10 days, to suffer from the poultry symptom and do not have obvious change, still keep the preceding symptom of treatment.
Effectively: after referring to 10 days, suffer from the poultry symptom and change, the effect before symptom is better than treating.
Cure: after referring to 10 days, transference cure is suffered from poultry and is got well.Its numeral is included in the significant digits.
Symptom is arranged during end: after referring to 10 days, suffer from poultry and still have certain symptom, its symptom performance is better than before the treatment or does not have change, suffers from poultry and does not cure.Its numeral has been included in the numeral of invalid number and effective number.
The relative weight gain rate: refer to use behind the medicine rate of body weight gain with respect to matched group.
Result of the test is as shown in table 1.
4. conclusion:
Analyze by statistics from the result of the test of table 1, compound mequindox soluble powder treatment group, Mequindox treated powder group and colistin sulfate powder and matched group difference is (P＜0.01) extremely significantly.Curative effect of the present invention is better than existing two kinds of medicines.
Table 1
| Numbering | Group | Invalid number | Effective number | Cure a number | Symptom pig's head number is arranged during end | A dead number | The relative weight gain rate % |
| A | Matched group | 25 | 0 | 0 | 8 | 17 | 0 |
| B | 5% Mequindox powder | 8 | 17 | 15 | 5 | 5 | 61.2 |
| C | 2% colistin sulfate powder | 12 | 13 | 8 | 10 | 7 | 30.5 |
| D | Compound mequindox soluble powder | 2 | 23 | 21 | 3 | 1 | 90.0 |
Claims (6)
1. compound mequindox soluble powder that is used for the treatment of swine dysentery and escherichia coli MOI, it is characterized in that, made by following component by weight percentage: Mequindox is 2～10%, and colistin sulfate is 0.5～5%, sodium salicylate is 6～30%, and surplus is an oral glucose.
2. the compound mequindox soluble powder that is used for the treatment of swine dysentery and escherichia coli MOI according to claim 1, it is characterized in that, made by following component by weight percentage: Mequindox is 3～8%, colistin sulfate is 1～4%, sodium salicylate is 9～24%, and surplus is an oral glucose.
3. the compound mequindox soluble powder that is used for the treatment of swine dysentery and escherichia coli MOI according to claim 1, it is characterized in that, made by following component by weight percentage: Mequindox is 5%, and colistin sulfate is 2%, sodium salicylate is 15%, and surplus is an oral glucose.
4. a preparation method that is used for the treatment of the compound mequindox soluble powder of swine dysentery and escherichia coli MOI is characterized in that, comprises the steps:
(1) Mequindox, colistin sulfate, sodium salicylate, oral glucose are sieved respectively, standby;
(2) good Mequindox fully mixes in V word mixer with colistin sulfate, sodium salicylate to take by weighing sieve;
(3) will sieve again in the mixture that good oral glucose joins above-mentioned Mequindox and colistin sulfate, sodium salicylate, in common batch mixer, fully mix, discharging, sieve and obtain being used for the treatment of the compound mequindox soluble powder of swine dysentery and escherichia coli MOI, wherein be used for the treatment of in the compound mequindox soluble powder of swine dysentery and escherichia coli MOI and made by following component by weight percentage: Mequindox is 2～10%, colistin sulfate is 0.5～5%, sodium salicylate is 6～30%, and surplus is an oral glucose.
5. the preparation method that is used for the treatment of the compound mequindox soluble powder of swine dysentery and escherichia coli MOI according to claim 4, it is characterized in that described Mequindox is 3～8%, colistin sulfate is 1～4%, sodium salicylate is 9～24%, and surplus is an oral glucose.
6. the preparation method that is used for the treatment of the compound mequindox soluble powder of swine dysentery and escherichia coli MOI according to claim 4, it is characterized in that described Mequindox is 5%, colistin sulfate is 2%, sodium salicylate is 15%, and surplus is an oral glucose.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100526971A CN101301274B (en) | 2008-04-11 | 2008-04-11 | Compound mequindox soluble powder for animals and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100526971A CN101301274B (en) | 2008-04-11 | 2008-04-11 | Compound mequindox soluble powder for animals and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101301274A CN101301274A (en) | 2008-11-12 |
| CN101301274B true CN101301274B (en) | 2010-09-01 |
Family
ID=40111494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100526971A Expired - Fee Related CN101301274B (en) | 2008-04-11 | 2008-04-11 | Compound mequindox soluble powder for animals and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101301274B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853024B (en) * | 2018-07-27 | 2021-11-02 | 洛阳瑞华动物保健品有限公司 | Colistin sulfate soluble powder and preparation method thereof |
| CN111214436A (en) * | 2020-03-18 | 2020-06-02 | 潍坊富邦药业有限公司 | Method for preparing mequindox injection by inclusion process |
-
2008
- 2008-04-11 CN CN2008100526971A patent/CN101301274B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101301274A (en) | 2008-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2224918B1 (en) | Use of edta and its salts for prevention and treatment of bacterial intestinal diseases of pigs | |
| CN101698024A (en) | Traditional Chinese medicine for treating respiratory diseases and promoting growth for swine and preparation method thereof | |
| CN103494832B (en) | A kind of compound ivermectin albendazole transdermal agent for livestock and using method thereof | |
| CN101450067A (en) | Premixing agent for treating and preventing livestock and poultry respiratory disease | |
| CN101301274B (en) | Compound mequindox soluble powder for animals and preparation thereof | |
| CN101590019A (en) | Soluble compound doxycycline hyclate powder for animals and preparation method thereof | |
| CN100548301C (en) | Be used for the treatment of injection of swine dysentery and preparation method thereof | |
| CN101628109A (en) | Compound neomycin sulphate solution and preparation method thereof | |
| CN101670094A (en) | Compound gentamycin sulfate soluble powder and preparation method thereof | |
| CN102274318A (en) | Pure traditional Chinese medicine composition for treating poultry coccidiosis and preparation method thereof | |
| CN101966201A (en) | Compound norfloxacin nicotinic soluble powder and preparation method thereof | |
| CN101669959A (en) | Medical composite for treating livestock and poultry intestinal canal diseases and preparation method and application thereof | |
| CN101829129B (en) | Veterinary compound gentamycin sulfate injection and preparation method thereof | |
| CN101468025A (en) | Soluble powder for preventing and treating colibacillosis of fowl | |
| CN101297813A (en) | Compound niacin norfloxacin injection for animals and preparation thereof | |
| CN101966200A (en) | Composition for treating poultry digestive tract bacterial infection and preparation method thereof | |
| CN101653417A (en) | Compound colistin sulfate soluble powder for treating lamb dysentery and preparation method thereof | |
| CN101433543A (en) | Compound mequindox injection | |
| CN101653486A (en) | Compound Bailongsan for treating diarrhoea of nursery pig and preparation method thereof | |
| CN101297795B (en) | Compound florfenicol powder for animals and preparation thereof | |
| EP3838347B1 (en) | Evernimicin for treating diseases like necrotic enteritis | |
| CN101422477A (en) | Compound apramycin sulfate injection | |
| CN101653596A (en) | Soluble powder for treating canine colibacillosis and preparation method thereof | |
| CN115554339A (en) | Pharmaceutical composition for preventing and treating animal diarrhea and preparation method thereof | |
| CN101601676A (en) | Compound hydrochloric acid oxytetracycline soluble powder and preparation method that the treatment spirochaeta gallinarum infects |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100901 Termination date: 20130411 |